Eosinophil-associated disease after SARS-CoV-2 infection or vaccination: EGPA and related entities

Ghadah A. Alrehaili; Karina A. Keogh; Misbah Baqir

doi:10.36141/svdld.v42i3.16598

Eosinophil-associated disease after SARS-CoV-2 infection or vaccination: EGPA and related entities

Authors

Ghadah A. Alrehaili Princess Nourah Bint Abdul Rahman University, Riyadh, Saudi Arabia [Research Collaborator in the Division of Pulmonary and Critical Care Medicine (limited tenure), Mayo Clinic, Rochester, Minnesota]
Karina A. Keogh Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, USA
Misbah Baqir Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, USA

Keywords:

2019-nCoV vaccine mRNA-1273, Ad26COVS1, BNT162 vaccine, Churg-Strauss syndrome, COVID-19

Abstract

N/A

References

1. Kadkhoda K, Laurita K. Antineutrophil cytoplasmic antibodies and their association with clinical outcomes in hospitalized COVID-19 patients. Cell Death Discov. 2021;7(1):277. doi: 10.1038/s41420-021-00671-1

2. Nakazawa D, Shida H, Tomaru U, et al. Enhanced formation and disordered regulation of NETs in myeloperoxidase-ANCA-associated microscopic polyangiitis. J Am Soc Nephrol. 2014;25(5):990-7. doi: 10.1681/ASN.2013060606

3. Chan-Chung C, Ong CS, Chan LL, Tan EK. Eosinophilic granulomatosis with polyangiitis after COVID-19 vaccination. QJM. 2022;114(11):807-9. doi: 10.1093/qjmed/hcab273

4. Costanzo G, Ledda AG, Ghisu A, Vacca M, Firinu D, Del Giacco S. Eosinophilic granulomatosis with polyangiitis relapse after COVID-19 vaccination: a case report. Vaccines (Basel). 2021;10(1):13. doi: 10.3390/vaccines10010013

5. Ibrahim H, Alkhatib A, Meysami A. Eosinophilic granulomatosis with polyangiitis diagnosed in an elderly female after the second dose of mRNA vaccine against COVID-19. Cureus. 2022;14(1):e21176. doi: 10.7759/cureus.21176

6. Lee LE, Jeong W, Park YB, Jeong SJ, Lee SW. Clinical significance of antineutrophil cytoplasmic antibody positivity in patients infected with SARS-CoV-2. J Clin Med. 2022;11(14):4152. doi: 10.3390/jcm11144152

Downloads

Published

30-09-2025

Issue

Vol. 42 No. 3 (2025)

Section

Letter to Editor

License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite

Alrehaili GA, Keogh KA, Baqir M. Eosinophil-associated disease after SARS-CoV-2 infection or vaccination: EGPA and related entities. Sarcoidosis Vasc Diffuse Lung Dis [Internet]. 2025 Sep. 30 [cited 2025 Nov. 11];42(3):16598. Available from: https://mail.mattioli1885journals.com/index.php/sarcoidosis/article/view/16598

Download Citation